Skip to content

Acupuncture and Escitalopram for Treating Major Depression Clinical Study

Acupuncture and Escitalopram for Treating Major Depression Clinical Study (AE-TMDCS): Study Design of a Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05901571
Acronym
AE-TMDCS
Enrollment
216
Registered
2023-06-13
Start date
2026-11-01
Completion date
2030-02-01
Last updated
2026-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder, Major

Brief summary

We will be able to investigate in a sample of patients free of antidepressants whether acupuncture is more effective than placebo.

Detailed description

This is a multicenter, randomized, controlled, 2 by 2 factorial clinical trial for Major depression.

Interventions

OTHERacupuncture

The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include DU20(Baihui) and SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the "De Qi" sensation.

OTHERescitalopram

Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.

OTHERsham-acupuncure

In the sham acupuncture group, superficial skin penetration (2 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.

Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.

Sponsors

Shanghai 7th People's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Between 18 and 75 years of age with no gender-based restriction. 2. Fulfilling the diagnostic criteria of DSM-5 for major depressive disorder. 3. A Hamilton Rating Scale for Depression (HDRS-17) score ≥ 17 4. Ability to read and understand Mandarin Chinese, at least nine years of education, and willingness to adhere to the study protocol. 5. The absence of acupuncture treatment within at least 1 year. 6. Willingness to participate in the trial and provide written informed consent for the clinical trial.

Exclusion criteria

1. Lifetime or current neuropsychiatric conditions, such as bipolar disorder, schizophrenia, substance dependence or abuse, dementia, brain injury, epilepsy and so forth. 2. High suicide risk or presenting with suicidal ideation (a score of more than 2 points on the Suicide question of the HDRS-17) at the time of entry. 3. Medicated with antidepressant at the start of the trial or history of treatment failure to escitalopram. 4. Pregnancy or breastfeeding. 5. Subjects who have acute inflammation at the planned acupuncture site on the body or any other contraindication to acupuncture. 6. Candidates afraid of needles in general and reluctant to receive acupuncture in particular 7. Known or suspected clinically unstable systemic medical disorder (including cancer, organ failure, or severe diseases of the cardiovascular, severe hepatic or renal insufficiency). 8. Previous participation in other acupuncture trials.

Design outcomes

Primary

MeasureTime frameDescription
HDRS-17 scalefrom baseline to 10 weeksthe change in the HDRS-17 score

Secondary

MeasureTime frameDescription
Beck depression inventory scalefrom baseline to 10 weeksthe change in the Beck depression inventory score
The CGI(Clinical Global Impression) scalefrom baseline to 10 weeksthe change in the CGI
The GAD-7(General Anxiety Disorder) scalefrom baseline to 10 weeksthe change in the GAD-7
The Mini-Mental State Examination (MMSE) scalefrom baseline to 10 weeksthe change in the MMSE

Countries

China

Contacts

CONTACTZhenxiang Han, Dr.
hanxiang798007@163.com+8617701767768
PRINCIPAL_INVESTIGATORZhenxiang Han, Dr

Shanghai Seventh People's Hospital, Shanghai University of TCM

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026